[Story of a predictable death: the end of vitamin K antagonists?].
Lloret Linares
C
C
Service de médecine interne A, clinique thérapeutique, hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France.
Bergmann
J-F
JF
D000925:Anticoagulants / Q000009:adverse effects*; D001384:Azetidines / Q000009:adverse effects; D001596:Benzylamines / Q000009:adverse effects; D005602:France; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011655:Pulmonary Embolism / Q000139:chemically induced; D013923:Thromboembolism / Q000188:drug therapy; D013927:Thrombosis / Q000517:prevention & control; D020246:Venous Thrombosis / Q000139:chemically induced; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D014812:Vitamin K; C109573:melagatran